https://doi.org/10.55788/2ee316dd
Air pollution, classified as carcinogenic to humans, is a major public health concern [1]. Apart from increasing the risk of lung cancer, chronic exposure to air pollution is also suggested to increase the risk of breast cancer [2,3]. The prospective French E3N cohort (ca 100,000 women) was initiated in 1990 to investigate the risk factors associated with cancer, including breast cancer, and other major non-communicable diseases in women [4].
Prof. BĂ©atrice Fervers (Centre LĂ©on BĂ©rard, France) presented results from a case-control study, based on E3N data, of the association between breast cancer risk and long-term exposure to particulate matters (PM2.5, PM10) and nitrogen dioxide (NO2), levels of which were estimated at the womenâs residential and workplace addresses [5].
Participants, aged 40â65 years at inclusion, were followed over the period 1990â2011. Exposure to air pollution was compared in 2419 women with histologically confirmed invasive breast cancer and 2984 individually matched controls. Annual mean PM2.5, PM10 and NO2 concentration levels were estimated using a Land Use Regression (LUR) model (resolution 50m x 50m) and were assigned to women based on their geocoded residential and workplace addresses. The mean exposure was calculated for each woman from their inclusion into the E3N cohort to their index date (date of diagnosis of cases).
The results showed a statistically significant linear increase in breast cancer risk related to mean exposure to PM2.5 (adjusted odds ratio [OR] 1.28; 95% CI 1.00â1.63) for an increment of 10 ÎŒg/m3. A numerically, but not statistically significant, increased breast cancer risk was observed for PM10 (adjusted OR 1.09; 95% CI 0.92â1.30) and NO2 (adjusted OR 1.05; 95% CI 0.97â1.13) for an increment of 10 ÎŒg/m3. No effect of HR status or menopausal status was observed.
âThis study is the first to report breast cancer risk to be associated with long-term air pollution exposure at both residential and workplace location histories over 22 years,â concluded Prof. Fervers. âFuture studies should consider exposure during commuting, the relatively short part of the day that is associated with high exposure to air pollution.â
- Cancer Risk Factors Collaborators. Lancet 2022;400(10352):563â591.
- Hvidtfeldt UA, et al. Environ Res. 2021;193:110568.
- White AJ, et al. J Natl Cancer Inst. 2023; Sep 11. DOI: 10.1093/jnci/djad170.
- Clavel-Chapelon F, et al. Int J Epidemiol. 2015;44(3):801â809.
- Fervers B, et al. Long-term residential and workplace exposure to air pollution and breast cancer risk: A case-control study nested in the French E3N cohort from 1990 to 2011. Abstract 238MO, ESMO 2023, 20â24 October, Madrid, Spain.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Third-line datopotamab deruxtecan improves progression-free survival in previously treated metastatic HR+/HER2- breast cancer compared with chemotherapy Next Article
Addition of pembrolizumab promising in early-stage high-risk ER+/HER2- breast cancer »
« Third-line datopotamab deruxtecan improves progression-free survival in previously treated metastatic HR+/HER2- breast cancer compared with chemotherapy Next Article
Addition of pembrolizumab promising in early-stage high-risk ER+/HER2- breast cancer »
Table of Contents: ESMO 2023
Featured articles
The importance of detecting early NSCLC
Breast Cancer
Benefit of pembrolizumab in TNBC remains after 5 years of follow-up Â
Addition of pembrolizumab promising in early-stage high-risk ER+/HER2- breast cancer
Long-term air pollution exposure at both residential and workplace locations increases breast cancer risk
Third-line datopotamab deruxtecan improves progression-free survival in previously treated metastatic HR+/HER2- breast cancer compared with chemotherapy
Colorectal Cancer
Neoadjuvant nivolumab/relatlimab demonstrates 100% pathological response in MMRd colon cancer
Selective KRASG12C inhibitor sotorasib leads to superior PFS in colorectal cancer
Postoperative ctDNA predicts survival in colorectal cancer
Overall survival in patients with initially unresectable colorectal liver metastases does not depend on choice of induction regimenÂ
Lung Cancer
Perioperative nivolumab boosts event-free survival in NSCLC
Selective RET inhibitor selpercatinib doubles progression-free survival in RET-mutated NSCLC
Dato-DXd outperforms docetaxel in previously treated patients with metastatic NSCLC Â
First-line and second-line benefit of amivantamab in advanced, EGFR-mutated NSCLC
Upper Gastro-Intestinal Cancer
Perioperative durvalumab/FLOT improves pCR in gastric cancer
Active surveillance after neoadjuvant chemoradiotherapy in oesophageal cancer
FOLFIRINOX equals gemcitabine-based chemoradiotherapy in neoadjuvant setting for pancreatic cancer
Modified FLOT regime outperforms FOLFOX in advanced/metastatic gastric/gastroesophageal junction adenocarcinoma
Melanoma
Lifileucel induces a durable response in heavily pretreated mucosal melanoma
Darovasertib/crizotinib combination: a potential first-line therapy in metastatic uveal melanoma
Genito-Urinary Cancers
Two potential new first-line standards of care in metastatic urothelial cancer
LuPSMA and enzalutamide: a promising combination
No benefit of erdafitinib over pembrolizumab in urothelial cancer second-line therapy
Gynaecological Cancers
Addition of atezolizumab to chemotherapy and maintenance PARP inhibitor has no benefit in ovarian cancer
Short-induction chemotherapy improves survival in advanced cervical cancer
Neoadjuvant immune checkpoint blockade safe and effective in MMRd endometrial cancer
Featured Interviews
Can radiotracers predict response to PD-L1 inhibitors in early NSCLC?
The importance of detecting early NSCLC
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com